Want to see APLM full AI Analyst Report?
Top Page
Apollomics
(NASDAQ:APLM)
Select Model
Select Model
Rating:51Neutral
Price Target:
$24.50
▲(34.54% Upside)
Action:Reiterated
Date:08/22/26
The score is held down primarily by weak financial performance—continued losses, persistent negative free cash flow, and negative equity that heighten financing risk. Technicals provide meaningful support due to a clear uptrend and positive momentum. Valuation remains a modest offset because the negative P/E reflects unprofitable operations and there is no dividend support.
Positive Factors
Revenue Expansion
The sharp increase indicates improved partnering or commercial activity and could provide a larger base for future development funding. Its durability still depends on repeatable collaborations and product progress, but the scale-up is a meaningful change from 2024.
Negative Factors
Persistent Operating Losses
Losses remain substantial despite higher revenue, with 2025 EBIT near negative $9.5M and net loss near negative $10.9M. Persistent unprofitability limits internally funded R&D and makes value creation dependent on clinical, partnering, or financing success.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Expansion
The sharp increase indicates improved partnering or commercial activity and could provide a larger base for future development funding. Its durability still depends on repeatable collaborations and product progress, but the scale-up is a meaningful change from 2024.
Read all positive factors
Apollomics (APLM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.76M
Dividend YieldN/A
Average Volume (3M)72.65K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue GrowthN/A
EPS Growth86.10%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.80
Shares Outstanding2,196,052
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-8.48
Price to Sales (P/S)3.18
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda4.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Apollomics Business Overview & Revenue Model
Company Description
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated t...
How the Company Makes Money
Apollomics’ primary business model is typical of clinical-stage biopharmaceutical companies: it seeks to create value by advancing drug candidates through clinical trials and monetizing them via (a) partnering transactions and (b) eventual product...
Apollomics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
34
Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.50M | 198.00K | 821.00K | 323.00K | 2.00K |
| Gross Profit | 8.24M | 198.00K | 821.00K | 323.00K | 2.00K |
| EBITDA | -9.22M | -41.05M | -53.45M | -43.88M | -50.12M |
| Net Income | -10.94M | -53.86M | -172.60M | -240.81M | -94.80M |
Balance Sheet | |||||
| Total Assets | 6.71M | 13.10M | 55.39M | 76.47M | 123.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.28M | 9.77M | 37.82M | 54.61M | 94.48M |
| Total Debt | 643.00K | 966.00K | 4.66M | 991.00K | 325.41M |
| Total Liabilities | 9.90M | 8.23M | 14.15M | 524.60M | 336.30M |
| Stockholders Equity | -3.19M | 4.86M | 41.23M | -448.12M | -212.86M |
Cash Flow | |||||
| Free Cash Flow | -10.37M | -28.77M | -43.22M | -43.19M | -50.86M |
| Operating Cash Flow | -10.37M | -28.74M | -43.21M | -42.82M | -43.31M |
| Investing Cash Flow | 218.00K | 5.98M | 21.36M | 29.05M | -38.95M |
| Financing Cash Flow | 3.68M | 468.00K | 21.23M | -294.00K | -1.64M |
Apollomics Technical Analysis
Positive
18.21
Price Trends
18.85
Positive
16.57
Positive
17.51
Positive
Market Momentum
1.53
Negative
69.99
Neutral
68.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Positive. The current price of 18.21 is below the 20-day moving average (MA) of 19.36, below the 50-day MA of 18.85, and above the 200-day MA of 17.51, indicating a bullish trend. The MACD of 1.53 indicates Negative momentum. The RSI at 69.99 is Neutral, neither overbought nor oversold. The STOCH value of 68.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APLM.
Apollomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $51.76M | -3.21 | 288.40% | ― | ― | 86.10% | |
46 Neutral | $16.00M | -0.08 | -302.13% | ― | -97.99% | 99.28% | |
43 Neutral | $10.64M | -3.23 | -70.74% | ― | 373.88% | -59.79% | |
42 Neutral | $8.51M | -0.88 | -179.41% | ― | ― | 23.05% | |
40 Underperform | $6.01M | -0.30 | -160.28% | ― | -84.26% | 14.73% |
* Healthcare Sector Average
APLM
Apollomics
24.33
18.29
302.75%
HIND
Vyome Holdings
2.25
-9.26
-80.45%
CLGN
Collplant Holdings
0.31
-2.21
-87.62%
LNAI
Lunai Bioworks
2.16
-16.96
-88.73%
XCUR
Exicure
1.15
-4.94
-81.12%
GDTC
CytoMed Therapeutics Limited
1.03
-0.82
-44.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.